Among the upregulated DEGs in the niraparib-treated group, SPHK1 was the most significantly changed gene, but the difference in expression between the tumor and the corresponding normal tissue was inconspicuous in breast and ovarian cancers according to the TCGA and GTEx databases (Supplementary Figures 1(a) and 1(b)). The gene discussed is SPHK1; the disease is ovarian carcinoma.